Di-diabody: A novel tetravalent bispecific antibody molecule by design

Journal of Immunological Methods

Volumn 279, Issue 1-2, 2003, Pages 219-232

  Lu, Dan ^a   Jimenez, Xenia ^a   Zhang, Haifan ^a   Atkins, Amanda ^a   Brennan, Laura ^a   Balderes, Paul ^a   Bohlen, Peter ^a   Witte, Larry ^a   Zhu, Zhenping ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Angiogenesis; Antibody engineering; CH 3 domain; Diabody; Endothelial cells; KDR Flt 1; Tetravalent bispecific antibody; VEGF VEGFR

Indexed keywords

BISPECIFIC ANTIBODY; TYROSINE KINASE RECEPTOR; VASCULOTROPIN;

AFFINITY CHROMATOGRAPHY; AMINO TERMINAL SEQUENCE; ANTIBODY COMBINING SITE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; GENE FUSION; HUMAN; HUMAN CELL; LIGAND BINDING; MAMMAL CELL; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL;

ESCHERICHIA COLI; MAMMALIA;

EID: 0142061073     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(03)00251-5     Document Type: Article

References (45)

1. Alt M., Muller R., Kontermann R.E. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett. 454:1999;90-94.
2. Cao Y., Suresh M.R. Bispecific antibodies as novel bioconjugates. Bioconjug. Chem. 9:1998;635-644.
3. Carter P. Bispecific human IgG by design. J. Immunol. Methods. 248:2001;7-15.
4. Carter P., Ridgway J., Zhu Z. Toward the production of bispecific antibody fragments for clinical applications. J. Hematotherapy. 4:1995;463-470.
5. Coloma M.J., Morrison S.L. Design and production of novel tetravalent bispecific antibodies. Nat. Biotechnol. 15:1997;159-163.
6. De Kruif J., Logtenberg T. Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J. Biol. Chem. 271:1996;7630-7634.
7. Dubel S., Breitling F., Kontermann R., Schmidt T., Skerra A., Little M. Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv). J. Immunol. Methods. 178:1995;201-209.
8. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol. 237:1999;1-30.
9. Folta-Stogniew E., Williams K.R. Determination of molecular masses of proteins in solution: implementation of HPLC size exclusion chromatography and laser light scattering. J. Biomol. Technol. 10:1999;51-63.
10. Hicklin D.J., Witte L., Zhu Z., Liao F., Wu Y., Li Y., Bohlen P. Monoclonal antibody strategies to block angiogenesis. Drug Discov. Today. 6:2001;517-528.
11. Holliger P., Prospero T., Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. U. S. A. 90:1993;6444-6448.
12. Hu S., Shively L., Raubitschek A., Sherman M., Williams L.E., Wong J.Y., Shively J.E., Wu A.M. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56:1996;3055-3061.
13. Kipriyanov S.M., Little M., Kropshofer H., Breitling F., Gotter S., Dubel S. Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion. Protein Eng. 9:1996;203-211.
14. Klagsbrum M., D'Amore P.A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 7:1996;259-270.
15. Kostelny S.A., Cole M.S., Tso J.Y. Formation of a bispecific antibody by the use of leucine zippers. J. Immunol. 148:1992;1547-1553.
16. Lu D., Kotanides H., Jimenez J., Zhou Q., Persaud K., Bohlen P., Witte L., Zhu Z. Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2. J. Immunol. Methods. 230:1999;159-171.
17. Lu D., Kussie P., Pytowski B., Persaud K., Bohlen P., Witte L., Zhu Z. Identification of residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies. J. Biol. Chem. 275:2000;14321-14330.
18. Lu D., Jimenez J., Zhang H., Wu Y., Bohlen P., Witte L., Zhu Z. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res. 61:2001;7002-7008.
19. Lu D., Jimenez J., Zhang H., Bohlen P., Witte L., Zhu Z. Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments. J. Immunol. Methods. 267:2002;213-226.
20. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N.R., Crystal R.G., Moore M.A., Hajjar K.A., Manova K., Benezra R., Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:2001;1194-1201.
21. Mack M., Riethmuller G., Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 92:1995;7021-7025.
22. Mallender W.D., Voss E.W. Jr. Construction, expression, and activity of a bivalent bispecific single-chain antibody. J. Biol. Chem. 269:1994;199-206.
23. Merchant A.M., Zhu Z., Yuan J., Goddard A., Adams C.W., Presta L.G., Carter P. An efficient route to human bispecific IgG. Nat. Biotechnol. 16:1998;677-681.
24. Müller K., Arndt K.M., Plückthun A. A dimeric bispecific miniantibody combines two specificities with avidity. FEBS Lett. 432:1998;45-49.
25. Müller K., Arndt K.M., Strittmatter W., Plückthun A. The first constant domain [C(H)1 and C(L)] of an antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Lett. 422:1998;259-264.
26. Pack P., Plückthun A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli. Biochemistry. 31:1992;1579-1584.
27. Pack P., Kujau M., Schroeckh V., Knupfer U., Wenderoth R., Riesenberg D., Plückthun A. Improved bivalent minantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Bio/technology. 11:1993;1271-1277.
28. Plückthun A., Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechology. 3:1997;83-105.
29. Rheinnecker M., Hardt C., Ilag L.L., Kufer P., Gruber R., Hoess A., Lupas A., Rottenberger C., Pluckthun A., Pack P. Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen. J. Immunol. 157:1996;2989-2997.
30. H3 domains for heavy chain heterodimerization. Protein Eng. 9:1996;617-621.
31. Schoonjans R., Willems A., Schoonooghe S., Fiers W., Grooten J., Mertens N. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J. Immunol. 165:2000;7050-7057.
32. Segal D.M., Weiner G.J., Weiner L.M. Introduction: bispecific antibodies. J. Immunol. Methods. 248:2001;1-6.
33. Suresh M.R., Cuello A.C., Milstein C. Bispecific monoclonal antibodies from hybrid hybridomas. Methods Enzymol. 121:1986;210-228.
34. Todorovska A., Roovers R.C., Dolezal O., Kortt A.A., Hoogenboom H.R., Hudson P.J. Design and application of diabodies, triabodies, and tetrabodies for cancer targeting. J. Immunol. Methods. 248:2001;47-66.
35. van Spriel A.B., van Ojik H.H., van de Winkel J.G.J. Immunotherapeutic perspective for bispecific antibodies. Immuol. Today. 21:2000;391-397.
36. Weiner L.M., Alpaugh R.K., von Mehren M. Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins. Cancer Immunol. Immunother. 45:1997;190-192.
37. Whitlow M., Filpula D., Rollence M.L., Feng S.L., Wood J.F. Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. Protein Eng. 7:1994;1017-1026.
38. 2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity. Protein Eng. 8:1995;1057-1062.
39. Zhu Z., Ghose T., Lee S.H.S., Fernandez L.A., Kerr L.A., Donohue J.H., McKean D.J. Tumor localization and therapeutic potential of an antitumor-anti-CD3 heteroconjugate antibody in human renal cell carcinoma xenograft models. Cancer Lett. 86:1994;127-134.
40. HER2 overexpressing tumor cells. Int. J. Cancer. 62:1995;319-324.
41. Zhu Z., Zapata G., Shalaby M.R., Snedecor B., Chen H., Carter P. High level secretion of a humanized bispecific diabody from Escherichia coli. Bio/technology (NY). 14:1996;192-196.
42. Zhu Z., Presta L.G., Zapata G., Carter P. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci. 6:1997;781-788.
43. Zhu Z., Rockwell P., Lu D., Kotanides H., Pytowski B., Hicklin D.J., Bohlen P., Witte L. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single chain antibodies from a phage display library. Cancer Res. 58:1998;3209-3214.
44. Zhu Z., Bohlen P., Witte L. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr. Cancer Drug Targets. 2:2002;135-156.
45. Zhuang Z., Jimenez X., Witte L., Zhu Z. An efficient route to the production of an IgG-like bispecific antibody. Protein Eng. 13:2000;361-367.